Abstract
Nosocomial pneumonia, especially ventilator-associated pneumonia (VAP), is a major cause of morbidity and mortality in the intensive care unit (ICU). This article discusses updates on bacterial resistance relevant to VAP, with a focus on methicillin-resistant Staphylococcus aureus (MRSA), treating MRSA pneumonia in the ICU, the use of tigecycline and doripenem for hospital-acquired pneumonia and VAP, and the potential utility of inhaled antibiotics as an alternative in the treatment of patients with VAP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
